Genfit S.A. - Asset Resilience Ratio
Genfit S.A. (GNFT) has an Asset Resilience Ratio of 0.78% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Genfit S.A. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Genfit S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see GNFT total assets.
Liquid Assets Composition Over Time
This chart breaks down Genfit S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore GNFT long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.18 Million | 0.78% |
| Total Liquid Assets | $1.18 Million | 0.78% |
Asset Resilience Insights
- Limited Liquidity: Genfit S.A. maintains only 0.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genfit S.A. Industry Peers by Asset Resilience Ratio
Compare Genfit S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Genfit S.A. (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Genfit S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.78% | $1.18 Million | $151.42 Million | +0.78pp |
| 2023-12-31 | 0.00% | $1.00K | $173.87 Million | -2.11pp |
| 2022-12-31 | 2.11% | $4.55 Million | $215.54 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $281.72 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $309.85 Million | -- |
| 2018-12-31 | 54.17% | $124.32 Million | $229.48 Million | +6.77pp |
| 2017-12-31 | 47.40% | $138.97 Million | $293.18 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $166.21 Million | -- |
| 2015-12-31 | 0.03% | $22.00K | $69.26 Million | -4.61pp |
| 2014-12-31 | 4.64% | $4.01 Million | $86.37 Million | +4.64pp |
| 2013-12-31 | 0.00% | $400.00 | $29.15 Million | -0.07pp |
| 2012-12-31 | 0.08% | $18.00K | $23.58 Million | +0.03pp |
| 2011-12-31 | 0.05% | $13.80K | $29.08 Million | -1.96pp |
| 2008-12-31 | 2.00% | $921.40K | $45.99 Million | -1.85pp |
| 2007-12-31 | 3.85% | $1.55 Million | $40.21 Million | +0.60pp |
| 2006-12-31 | 3.25% | $1.50 Million | $46.24 Million | -2.21pp |
| 2005-12-31 | 5.46% | $1.68 Million | $30.83 Million | -33.51pp |
| 2004-12-31 | 38.96% | $11.93 Million | $30.61 Million | -- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more